Pharmacokinetics of 450mg ropivacaine with and without epinephrine for combined femoral and sciatic nerve block in lower extremity surgery. A pilot study

British Journal of Clinical Pharmacology

Volumn 75, Issue 5, 2013, Pages 1321-1327

  Schoenmakers, Karin P W ^a   Vree, Tom B ^a   Jack, Nigel T M ^a   Van den Bemt, Bart ^a   Van Limbeek, Jacques ^a   Stienstra, Rudolf ^a  

^a Sint Maartenskliniek ^*  (Netherlands)

Author keywords

Anaesthetic techniques; Anaesthetics local; Pharmacokinetics; Regional; Ropivacaine

Indexed keywords

ADRENALIN; ROPIVACAINE; AMIDE; LOCAL ANESTHETIC AGENT; VASOCONSTRICTOR AGENT;

ADULT; ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION; ARTICLE; CLINICAL ARTICLE; FEMALE; FEMORAL NERVE BLOCK; HUMAN; LOWER LEG; MALE; NERVE BLOCK; ORTHOPEDIC SURGERY; PILOT STUDY; PRIORITY JOURNAL; SCIATIC NERVE BLOCK; ADOLESCENT; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECT; DRUG INTERACTION; FEMORAL NERVE; METHODOLOGY; MIDDLE AGED; RANDOMIZATION; SCIATIC NERVE;

ADOLESCENT; ADULT; AMIDES; ANESTHETICS, LOCAL; ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; EPINEPHRINE; FEMALE; FEMORAL NERVE; HUMANS; MALE; MIDDLE AGED; NERVE BLOCK; PILOT PROJECTS; RANDOM ALLOCATION; SCIATIC NERVE; VASOCONSTRICTOR AGENTS; YOUNG ADULT;

EID: 84876066364     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2012.04470.x     Document Type: Article

References (20)

1. Rosenberg PH, Veering BT, Urmey WF. Maximum recommended doses of local anesthetics: a multifactorial concept. Reg Anesth Pain Med 2004; 29: 564-575.
2. Heavner JE. Let's abandon blanket maximum recommended doses of local anesthetics. Reg Anesth Pain Med 2004; 29: 524.
3. Leone S, Di Cianni S, Casati A, Fanelli G. Pharmacology, toxicology, and clinical use of new long acting local anesthetics, ropivacaine and levobupivacaine. Acta Biomed 2008; 79: 92-105.
4. Simpson D, Curran MP, Oldfield V, Keating GM. Ropivacaine: a review of its use in regional anaesthesia and acute pain management. Drugs 2005; 65: 2675-2717.
5. Mulroy MF, Hejtmanek MR. Prevention of local anesthetic systemic toxicity. Reg Anesth Pain Med 2010; 35: 177-180.
6. Karmakar MK, Ho AM, Law BK, Wong AS, Shafer SL, Gin T. Arterial and venous pharmacokinetics of ropivacaine with and without epinephrine after thoracic paravertebral block. Anesthesiology 2005; 103: 704-711.
7. Lee BB, Ngan Kee WD, Plummer JL, Karmakar MK, Wong AS. The effect of the addition of epinephrine on early systemic absorption of epidural ropivacaine in humans. Anesth Analg 2002; 95: 1402-1407.
8. Ratajczak-Enselme M, Estebe JP, Rose FX, Wodey E, Malinovsky JM, Chevanne G, Dollo C, Ecoffey C, Le Corre P. Effect of epinephrine on epidural, intrathecal, and plasma pharmacokinetics of ropivacaine and bupivacaine in sheep. Br J Anaesth 2007; 99: 881-890.
9. Hickey R, Blanchard J, Hoffman J, Sjovall J, Ramamurthy S. Plasma concentrations of ropivacaine given with or without epinephrine for brachial plexus block. Can J Anaesth 1990; 37: 878-882.
10. Weber A, Fournier R, Van Gessel E, Riand N, Gamulin Z. Epinephrine does not prolong the analgesia of 20ml ropivacaine 0.5% or 0.2% in a femoral three-in-one block. Anesth Analg 2001; 93: 1327-1331.
11. Mansour NY. Reevaluating the sciatic nerve block: another landmark for consideration. Reg Anesth 1993; 18: 322-323.
12. Proost JH, Meijer DK. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med 1992; 22: 155-163.
13. Cuvillon P, Nouvellon E, Ripart J, Boyer JC, Dehour L, Mahamat A, L'Hermite J, Boisson C, Vialles N, Lefrant JY, De la Coussaye JE. A comparison of the pharmacodynamics and pharmacokinetics of bupivacaine, ropivacaine (with epinephrine) and their equal volume mixtures with lidocaine used for femoral and sciatic nerve blocks: a double-blind randomized study. Anesth Analg 2009; 108: 641-649.
14. Vanterpool S, Steele SM, Nielsen KC, Tucker M, Klein SM. Combined lumbar-plexus and sciatic-nerve blocks: an analysis of plasma ropivacaine concentrations. Reg Anesth Pain Med 2006; 31: 417-421.
15. Wank W, Büttner J, Maier KR, Emanuelson BM, Selander D. Pharmacokinetics and efficacy of 40ml ropivacaine 7.5mg/ml (300mg), for axillary brachial plexus block - an open pilot study. Eur J Drug Metab Pharmacokinet 2002; 27: 53-59.
16. Pere P, Salonen M, Jokinen M, Rosenberg PH, Neuvonen PJ, Haasio J. Pharmacokinetics of ropivacaine in uremic and nonuremic patients after axillary brachial plexus block. Anesth Analg 2003; 96: 563-569.
17. SPC Naropin 7.5mg/ml. Available at http://www.medicines.org.uk/emc/medicine/7289 (last accessed 14 December 2011).
18. Knudsen K, Beckman Suurkula M, Blomberg S, Sjovall J, Edvardsson N. Central nervous and cardiovascular effects of i.v. infusions of ropivacaine, bupivacaine and placebo in volunteers. Br J Anaesth 1997; 78: 507-514.
19. Bernards CM, Kopacz DJ. Effect of epinephrine on lidocaine clearance in vivo: a microdialysis study in humans. Anesthesiology 1999; 91: 962-968.
20. Van Obbergh LJ, Roelants FA, Veyckemans F, Verbeeck RK. In children, the addition of epinephrine modifies the pharmacokinetics of ropivacaine injected caudally. Can J Anaesth 2003; 50: 593-598.